

CITATION REPORT

List of articles citing

Non-invasive markers for hepatic fibrosis

DOI: 10.1186/1471-230x-11-91
BMC Gastroenterology, 2011, 11, 91.

Source: <https://exaly.com/paper-pdf/51428004/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
218	Glial Fibrillary Acidic Protein (GFAP) as a Mesenchymal marker of Early Hepatic Stellate Cells Activation in Liver Fibrosis in Chronic Hepatitis C Infection. 2014 , 30, 1027-32		6
217	Increased liver stiffness denotes hepatic dysfunction and mortality risk in critically ill non-cirrhotic patients at a medical ICU. 2011 , 15, R266		46
216	The future developments in hepatology: no need for a jaundiced view. 2012 , 3, i47-i52		2
215	Transient elastography and serum biomarkers: two-step screening methods for liver fibrosis in non-alcoholic fatty liver disease before liver biopsy. 2012 , 6, 377-80		2
214	Clinical utility of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 concentrations in the assessment of liver fibrosis due to chronic hepatitis B. 2012 , 40, 631-9		8
213	Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects?. 2012 , 6, 743-57		7
212	Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target?. 2012 , 3, 149		46
211	Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. 2012 , 54, 1465-72		63
210	The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. 2012 , 46, 518-25		48
209	Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. 2012 , 57, 549-55		85
208	HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway. <i>PLoS ONE</i> , 2012 , 7, e43408	3.7	35
207	Cirrhosis and other liver disease in cystic fibrosis. 2013 , 12, 116-24		104
206	Virtual laparoscopy: Initial experience with three-dimensional ultrasonography to characterize hepatic surface features. 2013 , 82, 929-34		3
205	Markers in nonalcoholic steatohepatitis. 2013 , 61, 67-125		12
204	Efficacy of HGF carried by ultrasound microbubble-cationic nano-liposomes complex for treating hepatic fibrosis in a bile duct ligation rat model, and its relationship with the diffusion-weighted MRI parameters. 2013 , 37, 602-7		13
203	Liver disease as a cause of thrombocytopenia. 2013 , 106, 425-31		14
202	Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. 2013 , 305, G483-95		153

201	The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. 2013 , 59, 236-42		184
200	Magnetic resonance elastography in the diagnosis of hepatic fibrosis. 2013 , 34, 81-8		30
199	Role of liver biopsy in the era of direct-acting antivirals. 2013 , 15, 307		17
198	Serum fibrinogen alpha C-chain 5.9 kDa fragment as a biomarker for early detection of hepatic fibrosis related to hepatitis C virus. 2013 , 7, 424-31		15
197	Egy-score predicts severe hepatic fibrosis and cirrhosis in Egyptians with chronic liver diseases: a pilot study. 2013 , 13, e10810		6
196	Recommendations for the management of hepatitis C virus infection among people who inject drugs. 2013 , 57 Suppl 2, S129-37		87
195	Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. 2013 , 38, 1086-96		73
194	Protein fingerprinting of the extracellular matrix remodelling in a rat model of liver fibrosis--a serological evaluation. 2013 , 33, 439-47		43
193	The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. 2013 , 20, 745-60		70
192	Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients. 2013 , 47, 457-60		1
191	Knowledge-based identification of soluble biomarkers: hepatic fibrosis in NAFLD as an example. <i>PLoS ONE</i> , 2013 , 8, e56009	3-7	9
190	Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>PLoS ONE</i> , 2013 , 8, e61448	3-7	30
189	Lymphocytes as liver damage mirror of HCV related adipogenesis deregulation. <i>PLoS ONE</i> , 2014 , 9, e92343	3-7	6
188	Systems level analysis and identification of pathways and networks associated with liver fibrosis. <i>PLoS ONE</i> , 2014 , 9, e112193	3-7	44
187	Noninvasive Biomarkers of Liver Fibrosis: An Overview. 2014 , 2014, 1-15		36
186	Value of reelin for assessing hepatic fibrogenesis in a group of Egyptian HCV infected patients. 2014 , 52, 1319-28		7
185	Guideline vs. practice in procollagen-3-aminopeptide monitoring. 2014 , 171, 1599-600		
184	Proteomic analysis of altered extracellular matrix turnover in bleomycin-induced pulmonary fibrosis. 2014 , 13, 1741-52		83

183	A comparison of FibroMeter [®] NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease. 2014 , 49, 1343-8		29
182	Cystic fibrosis related liver disease--another black box in hepatology. 2014 , 15, 13529-49		37
181	[Biomarkers for liver fibrosis: advances, advantages and disadvantages]. 2014 , 79, 187-99		11
180	Biomarkers for liver fibrosis: Advances, advantages and disadvantages. 2014 , 79, 187-199		6
179	Determination of normal hepatic elasticity by using real-time shear-wave elastography. 2014 , 271, 895-900		53
178	The validity of serum markers for fibrosis staging in chronic hepatitis B and C. 2014 , 21, 930-7		82
177	Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. 2014 , 20, 2854-66		52
176	Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions. 2014 , 2, 245-256		27
175	Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. 2014 , 28, 2081-90		21
174	Labordiagnostik der Leberfibrose und der nichtalkoholischen Fettleber-Krankheit. 2014 , 38,		
173	Usefulness of evaluating hepatic elasticity using artificial acoustic radiation force ultrasonography before hepatectomy. 2014 , 44, 1308-19		11
172	Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. 2014 , 39, 3-14		66
171	Diagnostic accuracy of noninvasive markers of liver fibrosis in patients with psoriasis taking methotrexate: a systematic review and meta-analysis. 2014 , 170, 1237-47		26
170	Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. 2014 , 60, 167-74		184
169	Alpha-fetoprotein level as a biomarker of liver fibrosis status: a cross-sectional study of 619 consecutive patients with chronic hepatitis B. <i>BMC Gastroenterology</i> , 2014 , 14, 145	3	22
168	Acoustic radiation force impulse elastography and serum fibrosis markers in chronic hepatitis C. 2014 , 49, 986-92		12
167	Von Willebrand Factor as a new marker for non-invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. 2014 , 39, 331-8		45
166	. 2015 ,		

165	The effect of applied transducer force on acoustic radiation force impulse quantification within the left lobe of the liver. 2015 , 18, 100-106		3
164	Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease. 2015 , 27, 667-71		9
163	HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. 2015 , 22, 800-8		11
162	Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. 2015 , 30, 131-138		28
161	Non-invasive assessment of liver fibrosis in chronic viral hepatitis. 2015 , 45, 1243-51		12
160	Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease. 2015 , 27, 1149-53		14
159	Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. 2015 , 21, 11044-52		22
158	Turnover rates of hepatic collagen and circulating collagen-associated proteins in humans with chronic liver disease. <i>PLoS ONE</i> , 2015 , 10, e0123311	3-7	39
157	Laboratory diagnostics of non-alcoholic fatty liver disease. 2015 , 38,		0
156	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. 2015 , 101669-101669		
155	Suitability of using serum hyaluronic acid concentrations in the diagnosis of canine liver fibrosis. 2015 , 18, 873-8		13
154	Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. 2015 , 101671		
153	Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B. 2015 , 13, 1532-9.e1		15
152	[Options for non-invasive assessment of liver fibrosis based on clinical data]. 2015 , 156, 43-52		0
151	Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. 2015 , 35, 1054-62		28
150	Caffeine protects against alcohol-induced liver fibrosis by dampening the cAMP/PKA/CREB pathway in rat hepatic stellate cells. 2015 , 25, 340-52		53
149	Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in nonalcoholic fatty liver disease. 2015 , 165, 658-66		22
148	The promise of metabolic phenotyping in gastroenterology and hepatology. 2015 , 12, 458-71		48

147	Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. 2015 , 15, 607	74
146	Noninvasive Markers of Fibrosis in the Assessment of Cirrhosis. 2015 , 39-47	
145	Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. 2015 , 27, 137-41	27
144	Results of extracardiac conduit total cavopulmonary connection in 500 patients. 2015 , 48, 825-32; discussion 832	72
143	Recommendations for the management of hepatitis C virus infection among people who inject drugs. 2015 , 26, 1028-38	132
142	Biomarcadores, índices y algoritmos para el diagnóstico de fibrosis hepática en pacientes con hepatitis crónica por virus C. 2015 , 8, 179-187	
141	Metabolic phenotyping for enhanced mechanistic stratification of chronic hepatitis C-induced liver fibrosis. 2015 , 110, 159-69	27
140	S100A4 promotes liver fibrosis via activation of hepatic stellate cells. 2015 , 62, 156-64	85
139	Value of Egy-Score in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferase-to-platelet ratio index, FIB-4 and FornsSindex in chronic hepatitis C virus. 2015 , 45, 560-70	14
138	The Relationship between Inflammatory Marker Levels and Hepatitis C Virus Severity. 2016 , 2016, 2978479	10
137	Point Shear Wave Elastography in Assessment of Hepatic Fibrosis: Diagnostic Accuracy in Subjects With Native and Transplanted Livers Referred for Percutaneous Biopsy. 2016 , 32, 201-7	11
136	In vitro development and validation of a non-invasive (13)C-stable isotope assay for ornithine decarboxylase. 2016 , 10, 026009	1
135	Enteral autonomy, cirrhosis, and long term transplant-free survival in pediatric intestinal failure patients. 2016 , 51, 96-100	41
134	Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. 2016 , 15, 86-95	16
133	Liver and Spleen Stiffness Measurements by Point Shear Wave Elastography via Acoustic Radiation Force Impulse: Intraobserver and Interobserver Variability and Predictors of Variability in a US Population. 2016 , 35, 2373-2380	29
132	Autoimmunity against laminins. 2016 , 170, 39-52	10
131	Diagnosis of chronic liver disease: An overview. 2016 , 22, 348-353	1
130	Spotlight on the three main hepatic fibrogenic cells in HCV-infected patients: Multiple immunofluorescence and ultrastructure study. 2016 , 40, 276-87	3

129	Quantification of liver fibrosis via second harmonic imaging of the Glisson's capsule from liver surface. 2016 , 9, 351-63	28
128	Transient elastography and aspartate aminotransferase to platelet ratio predict liver injury in paediatric intestinal failure. 2016 , 36, 361-9	25
127	Comparison of multislice breath-hold and 3D respiratory triggered T1 ρ imaging of liver in healthy volunteers and liver cirrhosis patients in 3.0 T MRI. 2016 , 44, 906-13	7
126	Serum soluble urokinase-type plasminogen activator receptor and interferon- γ -induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. 2016 , 128, 28-33	16
125	New advances in the diagnosis of canine and feline liver and pancreatic disease. 2016 , 215, 87-95	24
124	Multiple approaches to assess fourteen non-invasive serum indexes for the diagnosis of liver fibrosis in chronic hepatitis C patients. 2016 , 49, 560-5	8
123	Gene Expression Patterns Associated With Histopathology in Toxic Liver Fibrosis. 2016 , 149, 67-88	36
122	Biomarkers of liver fibrosis detecting with electrochemical immunosensor on clinical serum. 2016 , 222, 127-132	14
121	Noninvasive Assessment of Liver Fibrosis Stage Using Ultrasound-Based Shear Wave Velocity Measurements and Serum Algorithms in Patients With Viral Hepatitis B: A Retrospective Cohort Study. 2017 , 36, 285-293	4
120	Extraction of cell-free DNA from urine, using polylysine-coated silica particles. 2017 , 409, 4021-4025	6
119	Stratified aspartate aminotransferase-to-platelet ratio index accurately predicts survival in hepatocellular carcinoma patients undergoing curative liver resection. 2017 , 39, 1010428317695944	4
118	Anti-fibrotic potential of human umbilical cord mononuclear cells and mouse bone marrow cells in CCl ₄ -induced liver fibrosis in mice. 2017 , 89, 1378-1386	6
117	High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana. 2017 , 4, ofx195	21
116	Non-invasive Diagnostics of Liver Fibrosis. 2017 , 44, 50-56	1
115	Early Detection of Liver Damage in Mexican Patients with Chronic Liver Disease. 2017 , 5, 49-57	11
114	The Impact of Human Pegivirus on CD4 Cell Count in HIV-Positive Persons in Botswana. 2017 , 4, ofx222	8
113	Ultrasound shear wave elastography and liver fibrosis: A Prospective Multicenter Study. <i>World Journal of Hepatology</i> , 2017 , 9, 38-47	3-4 34
112	An Attempt to Establish a Common Animal Model for Hepatorenal Fibrosis in Rats. 2017 , 2017, 8260508	2

111	Magnetic resonance imaging and spectroscopy for differential assessment of liver abnormalities induced by <i>Opisthorchis felinus</i> in an animal model. 2017 , 11, e0005778	5
110	Pathological process of liver sinusoidal endothelial cells in liver diseases. 2017 , 23, 7666-7677	41
109	High serum N-terminal propeptide of procollagen type III concentration is associated with liver diseases. 2017 , 12, 203-207	3
108	Evaluating Diagnostic Accuracy of Noninvasive Tests in Assessment of Significant Liver Fibrosis in Chronic Hepatitis C Egyptian Patients. 2018 , 31, 315-320	1
107	Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard?. 2018 , 1864, 1024-1036	29
106	Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence. 2018 , 30, 27-32	16
105	Hepatic Fibrosis in Dogs. 2018 , 32, 26-41	22
104	microRNA-1273g-3p is a useful non-invasive test for the prediction of liver fibrosis in patients with chronic hepatitis C. 2019 , 17, 1817-1824	2
103	Antifibrotic potential of bone marrow-derived mesenchymal stem cells in biliary atresia mice. 2018 , 18, 3983-3988	3
102	HIGHER VALUES IN LIVER ELASTOGRAPHY AND MELD SCORE ARE MORTALITY PREDICTORS ON LIVER TRANSPLANT WAITING LIST. 2018 , 31, e1360	2
101	Imaging Assessment of Hepatic Changes after Fontan Surgery. 2018 , 59, 1008-1014	6
100	Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. 2018 , 9, 1256	19
99	Prognostic value of aspartate aminotransferase to platelet ratio index as a noninvasive biomarker in patients with hepatocellular carcinoma: a meta-analysis. 2018 , 10, 3023-3032	2
98	A Rapid and Robust Diagnostic for Liver Fibrosis Using a Multichannel Polymer Sensor Array. 2018 , 30, e1800634	44
97	Structure, Function, and Responses to Injury. 2018 , 1-87	7
96	Chronic hepatitis B virus and liver fibrosis: A mathematical model. <i>PLoS ONE</i> , 2018 , 13, e0195037	3-7 7
95	Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. 2018 , 18, 713-722	5
94	Determination of liver fibrosis stages in Egyptian chronic hepatitis B patients by a noninvasive tool. 2019 , 49, 1145-1150	0

93	Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. <i>Cells</i> , 2019 , 8,	7.9	59
92	Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. 2019 , 33, 451-463		8
91	A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests. 2019 , 55,		6
90	Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. 2019 , 42, 1257-1272		33
89	A PDGFR β -based score predicts significant liver fibrosis in patients with chronic alcohol abuse, NAFLD and viral liver disease. 2019 , 43, 501-512		11
88	Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease. <i>PLoS ONE</i> , 2019 , 14, e0212771	3.7	10
87	Preoperative evaluation of the degree of liver fibrosis based on matter-element analysis using serological indicators in patients with hepatocellular carcinoma. 2019 , 13, 70-76		7
86	Association between Aspartate Aminotransferase-to-Platelet Ratio Index and Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis: A Meta-Analysis of Cohort Study. 2019 , 2019, 2046825		4
85	A Noninvasive Method-Shear-Wave Elastography Compared With Transient Elastography in Evaluation of Liver Fibrosis in Patients With Chronic Hepatitis B. 2019 , 35, 147-152		13
84	Effect of alcohol on the interleukin 6-mediated inflammatory response in a new mouse model of acute-on-chronic liver injury. 2019 , 1865, 298-307		11
83	Significance of biglycan and osteopontin as non-invasive markers of liver fibrosis in patients with chronic hepatitis B virus and chronic hepatitis C virus. 2019 , 67, 681-685		6
82	Platelet indices significantly correlate with liver fibrosis in HCV-infected patients. <i>PLoS ONE</i> , 2020 , 15, e0227544	3.7	7
81	Volumetric multicomponent T relaxation mapping of the human liver under free breathing at 3T. 2020 , 83, 2042-2050		6
80	Biomarkers of liver fibrosis: prospective comparison of multimodal magnetic resonance, serum algorithms and transient elastography. 2020 , 55, 848-859		4
79	MR elastography of liver: current status and future perspectives. <i>Abdominal Radiology</i> , 2020 , 45, 3444-3462		16
78	Liver Sinusoidal Endothelial Cells at the Crossroad of Iron Overload and Liver Fibrosis. 2021 , 35, 474-486		4
77	Noninvasive biomarkers predict improvement in liver fibrosis after successful generic DAAs based therapy of chronic hepatitis C in Egypt. 2020 , 8, 1177-1188		3
76	Cognitive and neurophysiological assessment of patients with minimal hepatic encephalopathy in Brazil. 2020 , 10, 8610		1

75	New LncRNAs in Chronic Hepatitis C progression: from fibrosis to hepatocellular carcinoma. 2020 , 10, 9886		4
74	Liver stiffness measured by MR elastography is a predictor of early HCC recurrence after treatment. 2020 , 30, 4182-4192		15
73	Association of novel markers of liver disease with neonatal liver disease in premature baboons, Papio sp. <i>PLoS ONE</i> , 2020 , 15, e0228985	3-7	
72	Extraction of urinary cell-free DNA by using triamine-modified silica particles for liquid biopsy. 2020 , 412, 5647-5652		3
71	The Utility of Retinol-Binding Protein 4 in Predicting Liver Fibrosis in Chronic Hepatitis C Patients in Response to Direct-Acting Antivirals. 2020 , 13, 53-63		1
70	Collagen biology and non-invasive biomarkers of liver fibrosis. 2020 , 40, 736-750		38
69	The Endothelium as a Driver of Liver Fibrosis and Regeneration. <i>Cells</i> , 2020 , 9,	7-9	34
68	FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study. 2021 , 7, 111-116		2
67	Noninvasive Staging of Liver Fibrosis Using 5-Minute Delayed Dual-Energy CT: Comparison with US Elastography and Correlation with Histologic Findings. 2021 , 298, 600-608		7
66	PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. 2021 , 20, 205-212		11
65	Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell. 2021 , 36, 2706-2714		4
64	Nomogram for predicting advanced liver fibrosis and cirrhosis in patients with chronic liver disease. <i>BMC Gastroenterology</i> , 2021 , 21, 190	3	2
63	Non-invasive staging of liver fibrosis by two-dimensional shear wave elastography (2D-SWE) in patients with chronic hepatitis C and B. 2021 , 52,		
62	Predictive values of biochemical markers as early indicators for severe COVID-19 cases in admission. 2021 , 16, 353-367		4
61	Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. 2021 , 13,		
60	Hepatic steatosis as measured by the computed attenuation parameter predicts fibrosis in long-term methotrexate use. e20200040		
59	Pentraxin-3: A Novel Marker for Indicating Liver Fibrosis in Chronic Hepatitis B Patients?. 2021 , 32, 581-585		1
58	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. 2021 , 75, 1292-1300		5

57	Detection of liver fibrosis stages in patients with hepatitis C virus infection by non-invasive tool. <i>Egyptian Liver Journal</i> , 2021 , 11,	1.6	1
56	Assessment of Lifestyle Factors Helps to Identify Liver Fibrosis Due to Non-Alcoholic Fatty Liver Disease in Obesity. 2021 , 13,		3
55	Fibrinogen EChain as a Serum Marker of Liver Disease. 2017 , 493-511		0
54	Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease. <i>PLoS ONE</i> , 2013 , 8, e58955	3.7	25
53	Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. <i>PLoS ONE</i> , 2014 , 9, e89789	3.7	18
52	The N-terminal propeptide of type III procollagen in patients with acute coronary syndrome: a link between left ventricular end-diastolic pressure and cardiovascular events. <i>PLoS ONE</i> , 2015 , 10, e114097	3.7	5
51	Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy. <i>PLoS ONE</i> , 2016 , 11, e0155094	3.7	38
50	Diagnostic value of circulating microRNAs for liver cirrhosis: a meta-analysis. 2018 , 9, 5397-5405		4
49	Value of MR diffusion imaging in hepatic fibrosis and its correlations with serum indices. 2014 , 20, 7964-70		8
48	Aspartate transaminase to platelet ratio index in hepatitis C virus and Schistosomiasis coinfection. 2015 , 21, 13132-9		9
47	Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. 2016 , 22, 1367-81		21
46	Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. 2016 , 22, 9744-9751		7
45	Comparison of serum fibrosis biomarkers for diagnosing significant liver fibrosis in patients with chronic hepatitis B. 2020 , 20, 985-995		4
44	Mathematical modeling of liver fibrosis. 2017 , 14, 143-164		17
43	Serum angiopoietin-2 as a noninvasive diagnostic marker of stages of liver fibrosis in chronic hepatitis C patients. 2016 , 28, 140-148		1
42	Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. <i>World Journal of Hepatology</i> , 2015 , 7, 1192-208	3.4	7
41	Effect of ursodeoxycholic acid and vitamin E in the prevention of liver injury from methotrexate in pediatric leukemia. 2018 , 29, 203-209		12
40	Serum Levels of Annexin A2 as a Candidate Biomarker for Hepatic Fibrosis in Patients With Chronic Hepatitis B. 2015 , 15, e30655		7

- 39 SHFI: A Novel Noninvasive Predictive Model for Significant Fibrosis in Patients With Chronic Hepatitis B. **2018**, 18, 2
- 38 Metabolic Liver Disease: Part 2. **2014**, 185-214
- 37 [The diagnosis of hepatitis C virus infection]. **2014**, 155, 1019-23 0
- 36 Fibrinogen EChain as a Serum Marker of Liver Disease. **2015**, 1-20
- 35 Leberzirrhose und ihre Komplikationen. **2015**, 1-9
- 34 Serum Biomarkers for Evaluating Portal Hypertension. **2016**, 1-14
- 33 Leberzirrhose und ihre Komplikationen. **2016**, 259-266
- 32 Leberzirrhose und ihre Komplikationen. **2016**, 259-266
- 31 Pentraxin 3 (PTX3) as a Biomarker of Liver Disease. **2017**, 603-621 2
- 30 Serum Biomarkers for Evaluating Portal Hypertension. **2017**, 153-166
- 29 Clinicodiagnostic problems of hepatic fibrosis/cirrhosis. **2018**, 35, 98-107 1
- 28 PLATELETS, ASPARTATE AMINOTRANSFERASE, TUMOR NECROSIS FACTOR- γ LABORATORY PANEL FOR DIAGNOSIS OF LIVER FIBROSIS STAGE. **2019**, 34, 124-129
- 27 Comparison of non-invasive methods of assessing liver fibrosis in combination ART-experienced Zimbabweans. **2019**, 20,
- 26 PLATELETS, ASPARTATE AMINOTRANSFERASE, TUMOR NECROSIS FACTOR- γ LABORATORY PANEL FOR DIAGNOSIS OF LIVER FIBROSIS STAGE. **2019**, 34, 124-129
- 25 COMPARISON OF NON-INVASIVE FIBROSIS SCORES BETWEEN ALCOHOLIC LIVER DISEASE PATIENTS AND HEALTHY NON-ALCOHOLICS IN SOUTH INDIAN POPULATION. **2019**, 6, 2084-2088
- 24 Features of therapy of alcoholic liver disease in persons of young age. **2020**, 174, 80-85
- 23 Noninvasive Biomarkers for Liver Fibrosis. **2020**, 427-441
- 22 Investigation of red blood cells from patients with diffuse liver diseases by combined dielectrophoresis and terahertz spectroscopy method. **2020**, 60,

21	A diagnostic model for cirrhosis in patients with non-alcoholic fatty liver disease: an artificial neural network approach. 2014 , 28, 116		4
20	FibroScan, aspartate aminotransferase and alanine aminotransferase ratio (AAR), aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the 4 factor (FIB-4), and their combinations in the assessment of liver fibrosis in patients with hepatitis B. 2015 , 8, 20876-82		9
19	Evaluation of hyaluronic acid, procollagen type III N-terminal peptide, and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis. 2016 , 80, 302-308		4
18	Novel biomarkers assist in detection of liver fibrosis in HCV patients. <i>Egyptian Liver Journal</i> , 2021 , 11,	1.6	0
17	Beyond the Liver Function Tests: A Radiologist's Guide to the Liver Blood Tests. <i>Radiographics</i> , 2021 , 210137	5.4	0
16	APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection.. <i>Journal of Family Medicine and Primary Care</i> , 2021 , 10, 4082-4088	1.5	2
15	Liver fibrosis quantification.. <i>Abdominal Radiology</i> , 2022 , 47, 1032	3	1
14	Dual-Energy Computed Tomography in Diffuse Liver Diseases. <i>Journal of Gastrointestinal and Abdominal Radiology</i> ,	0.2	1
13	Multi-omics analyses of early liver injury reveals cell-type-specific transcriptional and epigenomic shift.. <i>BMC Genomics</i> , 2021 , 22, 904	4.5	0
12	Potential role of noninvasive biomarkers during liver fibrosis.. <i>World Journal of Hepatology</i> , 2021 , 13, 1919-1935	3.4	2
11	Trends in indirect liver function marker testing in Wales from 2000 to 2017 and their association with age and sex: an observational study.. <i>BMJ Open Gastroenterology</i> , 2022 , 9,	3.9	
10	Noninvasive diagnosis of periportal fibrosis in schistosomiasis mansoni: A comprehensive review. <i>World Journal of Hepatology</i> , 2022 , 14, 696-707	3.4	0
9	Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis.. <i>Cells</i> , 2022 , 11,	7.9	0
8	Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients. <i>PLoS ONE</i> , 2022 , 17, e0271020	3.7	0
7	The Role and Significance of Non-invasive Methods, with a Particular Focus on Shear Wave Elastography in Hepatic Fibrosis Staging. 2022 , 10, 1607-1614		
6	Clinical importance of laboratory biomarkers in liver fibrosis. 2022 , 32,		0
5	Circulating thrombospondin 2 levels reflect fibrosis severity and disease activity in HCV-infected patients. 2022 , 12,		0
4	Feasibility, safety and tolerability of the CREB-binding protein/Ecatenin inhibitor OP-724 in patients with advanced primary biliary cholangitis: an investigator-initiated, open-label, non-randomised, two-centre, phase 1 study. 2022 , 9, e001001		0

- 3 The Experience of Using Multipotent Mesenchymal Stromal Cells in the Treatment of Severe Recurrent Cholangitis in Children with Biliary Atresia after Kasai Surgery. **2022**, 174, 164-173 ○
- 2 Liver Injury Patterns and Hepatic Toxicity among People Living with and without HIV and Attending Care in Urban Uganda. **2023**, 2023, 1-7 ○
- 1 Structure, Function and Responses to Injury. **2024**, 1-95 ○